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1. Introduction
McGraw-Hill Concise Dictionary of Modern Medicine [1] defines pulmonary-renal syndrome
(PRS) as an idiopathic condition characterized by pulmonary hemorrhage, rapid progressive
glomerulonephritis, and positive autoantibodies. Pulmonary-renal syndrome may be also
defined as a heterogeneous group of multisystem diseases – e.g. Goodpasture syndrome,
Wegener's granulomatosis, collagen vascular disease – in particular systemic lupus
erythematosus, polyarteritis nodosa, Henoch-Schönlein purpura, and various other
conditions, which all have prominent pulmonary and renal components. According to Sanders
[2] the strict definition of pulmonary-renal syndrome is the combined clinical picture of rapid
progressive glomerulonephritis and pulmonary capillaritis requiring histological
confirmation.
If we translate the definition into pathological nomenclature, pulmonary-renal syndrome is
defined as combination of diffuse alveolar hemorrhage (DAH) and immune crescent
glomerulonephritis. The essential substrate of all these changes is vasculitis, which is according
to contemporary nomenclature based mostly on morphological and histopathological criteria.
These criteria for the most common forms of vasculitides were introduced in 1994 by Jennette
et al. at the Chapel Hill Consensus Conference organized by the American College of
Rheumatology [3]. The inflammation of small vessels (microangiopathic vasculitis) restricts
blood flow to various organs and damages them. If correct diagnosis and appropriate
treatment are delayed the condition can be fatal. Prognosis is good when treatment begins
before onset of respiratory and renal failure. Because of the similarity in clinical picture,
differential diagnosis of these diseases at the bedside can be challenging.
The pathophysiology of the vasculitides is based on immunologic mechanisms. These appear
to play an active role in mediating the inflammatory response, but their exact mechanisms still
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remain poorly understood. Although the primary events that initiate this process remain
largely unknown, recent investigations have brought us closer to understanding some of the
critical pathways involved in disease and provided a rationale for the study of novel
therapeutic agents [4].
2. Historical sense of the term „pulmonary - renal syndrome”
The first mention on pulmonary-renal syndrome is dated to year 1919 when the „father of viral
pathology” in the United States Dr. Ernest William Goodpasture (1886 – 1960) published his
work “The Significance of Certain Pulmonary Lesions in Relation to the Etiology of Influenza
in American Journal of the Medical Sciences [5]. He described two cases from more than fifty
autopsies where in patients dying in the great flu pandemic (Spanish flu) no bacterial etiology
was confirmed. In one of the two patients massive alveolar hemorrhage and fulminant
glomerulonephritis were present. It was never discovered what underlying disease other than
influenza this patient may have had. Human influenza virus was described fourteen years
later by Laidlaw and coworkers [6]. In 1958 two Australian scientists Stanton and Tange in the
discussion of their paper analyzed Goodpasture´s old finding and associated pulmonary
hemorrhage with glomerulonephritis with the name of Dr. Goodpasture, as Goodpasture
syndrome [7]. According to the biography written by Collins (2010), E. Goodpasture did not
approve the association of his name with this syndrome [8]. In 1967 the discovery of anti-GBM
antibodies were associated with Goodpasture nephritis [9].
At present pulmonary-renal syndrome broadened the family of diseases, where diffuse
alveolar hemorrhage and immune crescent glomerulonephritis are participating. Therefore, it
is not possible to say only glomerular basement membrane (Goodpasture) disease means
pulmonary-renal syndrome. The term pulmonary-renal syndrome should be associated with
the term pulmonary-renal vasculitic syndromes [10].
3. Histopathology
Pathological expressions of vasculitis are not usually specific for a particular diagnostic catego‐
ry of vasculitis.  The primary pathology in the majority of pulmonary-renal syndrome is
inflammation and necrosis of vessel wall classified according to the Chapel Hill Consensus
Conference classification [3] as medium/small vessel vasculitis. Generally, inflammation affects
arterioles, capillaries and venules with two basic types of necrosis – fibrinoid and granuloma‐
tous. In the very early stage of inflammation there is a massive influx of polymorphonuclear
leukocytes and monocytes accumulating in the capillary space. Later the condition is accompa‐
nied by proteinacous exudate. Damage of the capillaries and disruption of basal membranes with
leakage of erythrocytes is followed by an influx of macrophages. Fibrinoid depositions cause the
formation of extracapillary (crescent) cell proliferation in the glomerulus [11]. Changes in lungs
give rise to isolated necrotic pulmonary capillaritis where damaged red blood cells migrate
directly into alveolar tissue resulting in alveolar haemorrhage [12].
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Jennette et al. [13] described pathologic features of different necrotizing vasculitis types
indicating various pathogenic mechanisms causing the injury. In anti-GBM disease or immune
complex disease the pathogenic complexes between antibodies and antigens are located
exclusively or predominantly in vessel walls. In patients with ANCA vasculitis, these
autoantibodies are in the interstitial fluid and also in the blood. ANCA activate neutrophils
and monocytes in blood vessels, as well as in interstitial tissue. Activation in the vessels causes
necrotizing vasculitis and activation in the tissues necrotizing tissue inflammation. Clinical
association of dominating organs in pulmonary-renal syndrome is shown in table 1.
Organ MPA GPA (WG) CSS GPS
Kidney 90 80 45 75
Lung 50 90 70 60
Table 1. Approximate frequency of organ system involvement (%)
Interstitial inflammation is accompanied by capillary trombosis, disintegration of blood vessel
wall, loss of integrity of tissue structures, epithelial cell hyperplasia, accumulation of red cells
(and later hemosiderin), depositions of proteins (immunoglobulins, immune-complex
proteins), interstitial fibrosis and atrophy. The actual picture is dependent on different organ
structure of lungs and kidneys, as well as on primary stimulus.
Presence of specific granulomatous inflammation is typical for granulomatosis with
polyangiitis (GPA, formerly Wegener´s granulomatosis) described and defined by Wegener
in 1939 [14] and Former in 1950 [15] respectively. Morphological detected recruitment of
inflammatory cells, as well as immune competent cells (T-cells, B, cells, macrophages) and
sometimes also giant-cells are confirmed by immunostaining of autoantibodies, detection of
cytokine release and oxygen-free radical formation.
Pulmonary-renal syndrome has a wide spectrum of organ histopathological changes. Severe
renal vascular damage can be accomapnied by absent or mild pulmonary changes. On the
other hand severe pulmonary injury can be followed by mild renal destruction or normal renal
histology.
3.1. Renal pathology
Renal pathology is expressed by various forms of glomerulonephritis (anti-GBM, immunocom‐
plex, necrotizing pauci-immune). In rare cases sequential development supposed to be of
pathogenic importance: injury caused by ANCA may uncover the Goodpasture antigen. The
concept that only one antigen may trigger another one requires further support [16].
Immunohistochemical classification of renal capillary vasculitides [17] based on renal biopsies
is characterized by the presence of:
1. anti GBM antibodies – type I crescentic GN
2. immune complexes – type II crescentic GN
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3. pauci-immune ( only circulating ANCA) – type III crescentic GN
3.2. Pulmonary pathology
The underlying pulmonary lesions (necrotic pulmonary capillaritis) are clinically expressed
as diffuse alveolar haemorrhage. Disruption and degradation of the pulmonary capillary wall
and interstitial matrix results in vessel wall destruction and necrosis. Cordier and Cottin [18]
found capillaritis as the most common pathological finding (60%) in ANCA-related
vasculitides with pulmonary complications. However, capillaritis was not observed in all
patients. It is likely that vessel inflammations may be overlooked in some cases if not
specifically searched [19].
According to recommendations of Jennette and Falk [20] an accurate precise clinical diagnosis
usually requires the integration of many different types of data, including clinical signs and
symptoms, associated diseases, histological pattern of inflammation (eg, granulomatous
versus necrotizing), immunopathological features (e.g. presence and composition of vascular
immunoglobulin deposits), and serological findings (cryoglobulins, hypocomplementemia,
hepatitis B antibodies, hepatitis C antibodies, ANCAs, anti–GBM antibodies, ANA). Specific
diagnosis of a vasculitis is very important because the prognosis and appropriate therapy vary
substantially among different types of vasculitis. Many attempts to re-evaluate and to refine
the present nomenclature of vasculitis were done, however the complexity of vasculitic
syndromes, as well as of pulmonary-renal syndrome complicates not only the estimation of
appropriate diagnosis, differential diagnosis but also hampers effective treatment.
4. Immunopathogenesis
Potentially accepted immunopathological mechanisms of pulmonary-renal syndrome involve
antiglomerular basement membrane antibodies, antineutrophil cytoplasm antibodies,
generation of immunocomplexes, activation of complement and haemocoagulation. Due to
different pathogenesis of pulmonary-renal syndrome in various clinical diagnoses, common
immunopathological features (except systemic inflammation) could not be specified. As seen
in most inflammatory diseases, the systemic response to insult may be as important as the
initial stimulus.
4.1. Genetical and environmental influence
The current understanding of autoimmune disorders suggests that some environmental
factors initiate disease in a genetically susceptible individual. The importance of genetic
factors, especially the genes of major histocompatibility complex has been increasingly
recognized in determining susceptibility to autoimmune diseases. Because of the low incidence
of all nosological entities of pulmonary-renal syndrome, it is not possible to examine the
inheritance of genes within affected families predisposing to this disease.
In pulmonary-renal syndrome, as in most autoimmune disorders, the precise initiating events
are not known. Exposure to hydrocarbons is known to cause damage to pulmonary/renal
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endothelial cells and so could expose components of the alveolar basement membrane to cells
of the immune system, initiating an immune response [21]. The induction of vasculitis seems
multifactorial, with interplay of environmental factors and genetic predisposition creating the
environment for development of disease [22].
4.2. Kidney-lung crosstalk
New experimental data have emerged in recent years focusing on the interactive effects of kidney
and lung dysfunction, and these studies have highlighted the pathophysiological importance of
proinflammatory and other immunologic pathways as well as the complex nature of interor‐
gan crosstalk. Because pulmonary and renal dysfunction frequently coexist, the effects of failure
of either organ are particularly relevant to the function of the other. Evidence suggests that
deleterious kidney-lung interactions or crosstalk rise, at least in part, due to the loss of the normal
balance of immune, inflammatory and soluble mediator metabolism. These processes occur after
severe insults and cause induction of organ injury [23]. Organ crosstalk is a consequence of both
direct loss of normal function and inflammatory dysregulation resulting from both organ failure.
Cellular (e.g. neutrophils) as well as soluble mediators (cytokines) contribute to the inflammato‐
ry dysregulation under these circumstances [24].
4.3. Immunology of inflammation
Interactions between inflammatory cells and damaged endothelium end in vessel
inflammation (vasculitis), the major manifestation of all clinical entities. Cytokines,
chemokines (such as IL-8) complement components, circulating immune complexes, and
antibodies can be primary determinants of initiators of endothelial cell damage. When focusing
on two basic clinical representatives – Goodpasture disease and granulomatosis with
polyangiitis, damage of the vessel wall of glomeruli and alveolar capillaries are caused by
antigen-stimulated white blood cells, anti-GBM antibodies and ANCA, respectively. In anti-
GBM and ANCA vasculitis, the pathologic finding of focal, lytic necrotizing injury suggests
highly effective local activation of neutrophils and monocytes with release of oxidants and
proteases that are neutralized beyond the site of injury [13].
Concurrent ANCA and anti-GBM antibody production can be seen in selected patients, but
reasonable explanation is unknown. It is possible that ANCA-related proteases damage or
expose the nephritogenic epitopes in cr3 (IV) collagen in GBM, and this in turn leads to anti-
GBM antibody production. It is unlikely that the crossreactivity between p-ANCA and anti-
GBM antibodies is derived from the same autoantibody repertoire, because there does not
appear to be a structural relationship between c-ANCA and a3 (IV) NC I collagen [25]. It is
currently unclear whether there is any structural cross-reactivity between c-ANCA and anti-
GBM antibodies [26].
4.4. Cellular and humoral mechanisms
Immunological mechanisms involved in initiation and prolongation of inflammatory state
could be divided to two groups: cellular mechanisms (activity of immune-competent cells) and
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humoral mechanisms (proteins, mediators). Inflammation is tightly connected also to
oxidative stress either through increased formation of ROS and/or the decreased activity of
antioxidant systems.
It should be postulated in the view of common association in all disease entities that the damage
is caused by free radical formation of injured tissues. Local release of inflammatory cytokines
and chemokines further activate endothelial cells to upregulate soluble adhesion molecules,
enhanced activation of neutrophils and generation of reactive oxygen species which serve to
amplify the initial inflammation leading to dysregulated apoptosis, secondary necrosis and
overt vascular injury.
The immune system may target the tissues due to structural alterations in proteins or cell
surfaces. Finally, the production of necessary anti-inflammatory factors may be impaired after
hypoxia. Initiating signals – triggers of inflammation can activate the inflammatory process
by several mechanisms that may occur simultaneously [27]:
1. Passively released factors from injured or exposed cells due to breakdown of cellular
barriers.
2. Stress or injury (hypoxia) can induce the active synthesis of pro-inflammatory signals.
3. Immune system receptors (cellular, humoral) may recognize altered or exposed surface
structures.
4. Damaged cells have decreased expression of inhibitory (anti-inflammatory) factors
permitting uncontrolled activation of inflammatory cells or systems.
Binding of ANCA to neutrophil membranes activates the cells leading to the release of lytic
enzymes, chemoatractant interleukin-8 and oxygen free radicals. Neutrophils subsequently
aggregate on endothelium causing inflammation and damage to the vasculature. Still, it
remains unclear in many diseases whether or not ANCAs are simply playing a bystander role
in the inflammatory cascade or directly driving vasculitic inflammation [28].
Gröne [29] describes except of the role of ANCAs, other immunopathogenetic factors
important in vasculitides. They include innate immunity factors, transcription factors such as
NFkB, endothelial cytoprotective agents such as NO. In summary:
1. ANCA may be directed against several antigens, in the majority of cases against
proteinase-3 and myeloperoxidase. The complex of proteinase-3 and ANCA leads to an
increased expression of CD14, CD18 and an elevated synthesis of cytokines and
chemokines such as interleukin 1, interleukin 8 in monocytes. In addition granulocytes
generate reactive oxygen species, ANCA may also bind to a surface glycoprotein (gp130)
expressed on glomerular and peritubular endothelia in the kidney. Thus the activation of
granulocytes, monocytes and endothelial cells by ANCA may be a critical step in the
initiation phases of vasculitis, ultimately leading to apoptosis.
2. NO is cytoprotective for endothelial cells in low concentrations.
3. The transcription factor complex NFkB is a key regulatory transcription factor for the
expression of genes and proteins associated with acute inflammatory processes and
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“endothelialitis”. Inhibition of NFkB activity by a decoy-oligonucleotide prevented
activation of endothelial cells in reperfusion injury and vascular rejection.
4. The complement system probably plays an essential role in the initiation and propagation
phases of vasculitis. Specifically the pneumococcal C-polysaccharide-reactive protein
(CRP), synthesized after trauma and infection, can potently activate the complement
cascade leading to activation of endothelial cells with increased expression of adhesion
molecules.
Above mentioned pathogenetic mechanisms of vasculitides seem to be important and com‐
mon factors for the generation and maintenance of vascular inflammation; nevertheless these
factors are only part of the spectrum of different humoral and cellular responses in vasculitis [29].
4.5. Ischemic/reperfusion injury
Acute onset of severe pulmonary-renal syndrome is closely connected with ischemia-
reperfusion injury when both innate and adaptive immunity contribute to their pathogenesis.
Kidney resident cells promote inflammation after ischemic/reperfusion injury by increasing
endothelial cell adhesion molecule expression and vascular permeability. Kidney epithelial
cells bind complement and express toll-like receptors and resident and infiltrating cells
produce cytokines/chemokines. Early activation of kidney dendritic cells initiates a cascade of
events leading to accumulation of interferon-γ-producing neutrophils, infiltrating
macrophages, CD4+ T cells, B cells and invariant natural killer T cells. Bajwa et al. [30] recently
implicated the IL23/IL17 pathway in kidney ischemic/reperfusion injury, as well as the
importance that T-regulatory cells can directly suppress the early innate inflammation,
induced by ischemia/reperfusion, in an IL-10 dependent manner. Following the initial early
phase of inflammation, the late phase involves infiltration of anti-inflammatory cells including
regulatory T cells, alternatively activated macrophages and stem cells leading to attenuation
of inflammation and initiation of repair.
4.6. TNFalfa – proinflammatory cytokine
Another possible connection between kidney and lung inflammation as a part of the systemic
inflammatory pathway describe Campanholle et al. [31]. They concluded that pro-inflammato‐
ry mediators, TNF-alfa, IL-1β and MCP-1, released by the ischemic kidney might reach the lungs,
induce inflammation, up-regulate COX-2 and iNOS expressions, and ultimately contribute to
the accumulation and to activation of neutrophils and mononuclear cells.
TNF-alpha, a potent pro-inflammatory cytokine belongs to the group of mediators that activate
leukocytes and endothelial cells. Neutrophils, other leukocytes, and platelets adhere via
cognate receptors to the pulmonary endothelium. Activated neutrophils release proteases,
leukotrienes, reactive oxygen intermediates, and other inflammatory molecules that amplify
the inflammatory response. ROS and proteases can directly damage alveolar–capillary
membrane integrity [32]. On the other side the lectin-like domain of TNF-alpha has positive
effects on permeability of the epithelial-endothelial barrier in the lungs. This domain is able
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to blunt ROS production in pulmonary artery endothelial cells under hypoxia and
reoxygenation, and reduce ROS content in inflammatory conditions [33].
TNF-alpha - an important cytokine involved in pathogenesis of inflammation, is an example
of a “moonlighting protein”, with differential activities mediated by its receptor-binding
versus its lectin-like domains, which opens the possibility to design and develop more
sophisticated therapeutic regimens for patients with increased permeability of the epithelial-
endothelial barrier of the lung, which in pulmonary-renal syndrome can occur. However, in
the future, more research is needed in order to reveal the underlying mechanisms of TNF’s
protective versus deleterious effects [34].
4.7. Reactive oxygen species and nitric oxide engagement
Among enzymes incorporated in the free radical formation, eNOS (NOS3) has been shown to
inhibit vascular inflammation in many different model systems, but its role in the pathogenesis
of vasculitis has not been elucidated yet. According to Schoeb et al. [35] eNOS serves as a
negative regulator of vasculitis in experimental (mice) model of pulmonary-renal syndrome
and they further suggest that nitric oxide produced by this enzyme may be critical for
inhibiting lesion formation and vascular damage in human vasculitides. Derangements in the
key oxidative stress enzymes, nitric oxide synthase and heme oxygenase may also facilitate
distant organ dysfunction. Disordered NO metabolism in the setting of inflammation is well
established. While the cause of this dysregulation is not entirely clear, asymmetric
dimethyarginine seems to play a significant role [36, 37]. Asymmetric dimethyarginine is an
inhibitor of endothelial NO synthase and shifts NO metabolism toward production of oxygen-
based free radicals [38]. MPO released from activated neutrophils are involved in the formation
of NO-derived reactive oxygen species [39]. ROS produced by macrophages in combination
with reactive nitrogen intermediates cause protein nitration in endothelial cells [40]. This could
be related to activation of cytokines produced by macrophages to elicit proinflammatory and
prothrombotic responses in endothelial cells [41]. MPO produces a highly deleterious reactive
oxygen species, the hypochlorous acid (HOCl). Anti-MPO antibodies from patients with small
vessel vasculitis (MPA) can trigger the release of MPO by neutrophils and monocytes. Anti-
MPO antibodies can activate MPO to generate an oxidative stress deleterious for the
endothelium.
Guilpain et al. [42] recently demonstrated that MPA sera with anti-MPO antibodies activated
MPO in vitro, and generated free radicals (hypochlorous acid), whereas sera from MPA
patients with no anti-MPO antibodies or healthy individuals did not. Free oxygen radical
production and endothelial lysis were abrogated by N-acetylcysteine (NAC), an antioxidant
molecule through the augmentation of glutathione biosynthesis. N-acetylcysteine significantly
reduced the activation of myeloperoxidase and improved the survival of endothelial cells
exposed to byproducts of myeloperoxidase activation. Thus, anti-MPO antibodies could play
a pathogenic role in vivo by triggering an oxidative burst leading to severe endothelial
damages.
Updates in the Diagnosis and Treatment of Vasculitis80
During early stage of human septic shock Spapen et al. [43] founded massive decrease of IL-8
after N-acetylcystein (NAC) administration. According to that finding, Park et al. [44] supposes
another possible mechanism of NAC effect - through inhibition of IL-8.
In Goodpasture´s syndrome normal exposure of epitopes by self-limited generation of ROS is
not itself sufficient to launch a fatal autoimmune response. ROS can be produced in response
to various normal stimuli such as mediators of inflammation, environmental toxins, de-novo
respiratory bursts. Excessive ROS may influence GBM degradation by proteolytic enzymes
[45]. Therefore, the presence of ROS in the microenvironment around the GBM can likely
activate several pathways of protein modification in renal, as well as in pulmonary tissue in
Goodpasture´s syndrome. Kalluri et al. [46] suggest that ROS can alter the hexameric structure
of type IV collagen to expose or destroy selectively immunologic epitopes embedded in
basement membrane. The reasons for autoimmunity in Goodpasture syndrome may lie in an
age-dependent deterioration in inhibitor function modulating oxidative damage to structural
molecules. ROS therefore may play an important role in shaping post-translational epitope
diversity or neoantigen formation in organ tissues.
4.8. Natural antibodies
Natural antibodies produced by B-cells may play a role in prevention of pathological
autoimmune reactions by binding to microbial epitopes that are similar or identical to self-
antigens [47].
Bacterial superantigens trigger the activation of autoreactive cells such as toxic shock
syndrome toxin 1 and Staphylococcal enterotoxins. These superantigens are generally
considered to be the triggers of exacerbation in Wegener´s granulomatosis [48, 49].
4.9. Role of Th 17
Under certain conditions, T helper type cells can differentiate into regulatory T cells producing
immunosuppressive cytokines such as transforming growth factor-ß and IL-10. These
regulatory T cells representing about 5% to 10% of CD4+ T cells in the steady state, play a
central role in immune homeostasis and in preventing autoimmune diseases in general [50,
51]. Regulatory T cells exist naturally and are called natural regulatory T cells expressing CD25
and Foxp3. T cells can also convert into regulatory T cells upon certain antigen recognition and
are called antigen-specific regulatory T cells that secrete IL-10 and/or transforming growth
factor-β. Indeed, regulatory T cells are required to control infection-induced immunity in a
host, including autoimmunity inhibition [52].
Recently discovered regulatory Th17-cells and cell-derived cytokines play an important role
in the pathogenesis of several autoimmune/inflammatory diseases including vasculitides. In
Wegener´s granulomatosis, regulatory T-cells display impaired suppressor activity potentially
favouring inflammation and break of tolerance [53]. Th17-cells produce several cytokines such
as IL-17, IL-21, IL-22, CCL-20 which induce massive inflammatory tissue reactions and these
cytokines also stimulate nonimmune cells (fibroblasts, endothelial and epithelial cells) to the
production of proinflammatory mediators (IL-6, TNF-alfa, prostaglandins, NO, MMP and
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chemokines [54]. New results, showing the possibility that regulatory Th17 cells and
corresponding cytokines (IL-17, IL-23) involved in the pathogenesis of GPS as well in WG
might be used for the directed therapy of pulmonary-renal syndrome in the future.
Vasculitis (especially Wegener´s granulomatosis) is associated with bacterial infection, in
particular nasal occurence of Staphylococcus aureus. Infection may play a role in the induction
of autoimmunity as well as in the effector phase of the disease. In this relation Tadema et al.
[55] emphasize the role of innate immunity that is involved in the development of a Th17-
driven immune response, consistent with skewing towards a Th17 T cell phenotype that has
been observed in Wegener's granulomatosis. Their findings shed new light on the potential
role of γ/δ T cells in host defense and inflammatory diseases, provide important new
information on the pathogenic role of IL-23 and IL-1β, and underline the importance of
targeting these cytokines in the development of new therapeutic interventions against many
autoimmune diseases.
Sutton et al. [56] demonstrated that γ/δ T cells activated by IL-1β and IL-23 are an important
source of innate IL-17 and IL-21 and provide an alternative mechanism whereby IL-1 and IL-23
may mediate autoimmune inflammation.
In other study Ooi et al. [57] suggested the importance of IL-23, a key cytokine in the induction
and maintenance of autoimmune responses, in Th1 responses that could play a role in some forms
of glomerulonephritis especially in anti-GBM (Goodpasture) disease. This experimental work
emphasizes potential mechanisms in the treatment of several forms of glomerulonephritis.
Accumulating data from animal models support a role for Th17 cells and their cytokines in
various autoimmune and inflammatory processes. Emerging data from running clinical trials
indicate the importance of Th17 cells in such immunological processes, too. Future studies will
allow us to evaluate the role of each cytokine independently in contributing to human diseases
with immune-mediated pathologies and to design optimal cytokine-targeted therapies for
these diseases [58].
4.10. Perspectives of treatment – modulation of inflammation
After careful analysis of numerous animal studies demonstrating the importance of inflamma‐
tion in the pathogenesis of pulmonary-renal syndrome, as well as the clinical correlates demon‐
strating activation of the same systems in patients with systemic autoimmunity, there is a reason
to hope that different modalities of anti-inflammatory treatment could ameliorate the course of
the disease. The inflammatory process is however extremely complex due to its multifactorial
etiology and considering also in the context of differences among systems [59]. For example renal
failure involves complex host-kidney interactions in which the inflammatory state of the host
contributes to the development of renal failure and injury of the inflamed tissue further modu‐
lates the inflammatory state of the host. One of the greatest obstacles to effective treatment is
establishing the diagnosis as early as possible based on all available diagnostic procedures,
including invasive ones. Earlier and more reliable identification of clinical signs and laboratory
markers has become an important tool in relation to establish effective treatment modalities. Once
the inflammatory response has been set in motion, treatment may be ineffective and could
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conceivably delay recovery. Strategies that prevent the initiation of inflammation by targeting
the earliest signals or recognition of the injured tissue may be of particular therapeutic benefit in
these conditions [25].
5. Semi-systemic (pathologic/clinical) classification
The etiology of pulmonary-renal syndrome could be associated with variety of diseases. A
possible classification based on clinical symptomatology and histopathology is described in
Table 2.
Etiology of pulmonary-renal syndrome
Cause Disease
Systemic vasculitides
Wegener's granulomatosis
Churg-Strauss syndrome
Cryoglobulinemia
Henoch-Schönlein purpura
Behçet's syndrome
Microscopic polyarteritis
Connective tissue disorders
Polymyositis or dermatomyositis
Progressive systemic sclerosis
RA
SLE
MCTD
“Catastrophic” APS
Renal disorders
Goodpasture´s disease
Idiopathic immune complex glomerulonephritis
IgA nephropathy
Rapidly progressive glomerulonephritis with heart failure
Other
Drugs (D-penicillamine, propylthiouracil, carbimazole, cocaine, …)
Post-renal transplation failure
Idiopathic pulmonary-renal syndrome
Infection
Coagulopathy
Heart failure
Table 2. Etiology of pulmonary-renal syndrome
6. Clinical involvement
It is very important to establish an early diagnosis based on clinical vigilance, contemporary
diagnostic laboratory support (immunology and biopsy) for the pulmonary-renal syndrome
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in order to avoid the severe consequences of rapid and irreversible loss of renal function or
from severe pulmonary hemorrhage. Both can be avoided by appropriate initial immunosup‐
pressive treatment [60]. In pulmonary-renal syndrome better understanding of interorgan-
crosstalk is of utmost importance, as current clinical care is many times limited to preventive
and supportive measures [24].
In main clinical entities (Goodpasture´s disease, ANCA associated vasculitis, SLE-associated
vasculitis) induction and maintenance immunosupression is achieved by steroids and
cyclophosphamide. Intensive plasma exchange to remove pathological antibodies,
proinflammatory cytokines, complement compounds and factors of coagulation from
circulation is beneficial for patients with pulmonary hemorrhage and severe kidney disease.
Except of antibody removal, plasma exchange may have also other immunoregulatory effects
and could potentiate the effects of immunosuppressive drugs [61]. Exchange procedures have
beneficial effect on long-term renal recovery [62, 63]. Severe renal function impairment
requires haemodialysis and progression to end stage renal failure renal replacement therapy
is required [17]. In case of inevitable ICU admission supportive care is important as well.
During immunosuppressive regimes nosocomial infection used to be a common complication
associated with high mortality [64]. Therefore minimizing the risk of infection has the highest
of high priority. Patients with pulmonary-renal syndrome are often hypotensive because of a
combination of dehydration, haemorrhage and systemic inflammatory response and may
therefore require inotropic support [28]. Endotracheal intubation, tracheostomy, lung
protective ventilation, transfusion and anticoagulation may be also necessary.
Antioxidant effect of N-acetylcystein published by Fernández-Fernández and Sesma [65] in
one patient with WG and also our unpublished experience suggests clinical improvement of
systemic inflammation. Administration of NAC is based on two significant studies: the
IFIGENIA trial in 2005 [66] (Idiopathic Pulmonary Fibrosis International Group Exploring N-
acetylcysteine I Annual study) and the study by Guilpain et al. [42]. Both studies have reported
that NAC significantly reduced the activation of MPO and improved the survival of
endothelial cells. In a recent experimental study by Lee et al. [67] continuous infusion of NAC
attenuated inflammatory response and acute lung and kidney injury after hemorrhagic shock
in rats. This result supports the clinical experience.
Some recent studies are focused on anti-TNF molecules, anti-B-cells blockers [68], anti-BlyS
[69], anti-IL5 molecules [70], antithymocyte globulin [71], blockers of costimulatory molecules
[72], tyrosine-kinase inhibitors [73] and proteasome inhibitors [74]. The results of these studies
are sometimes controversial but there is a real hope that they will provide useful knowledge
in the near future.
Many questions still remain unanswered also in the use of intravenous immunoglobulins
(IVIG). Such treatment should be considered as an effective regimen in many “off label”
indications particularly in cases where standard immunosuppressive regimes fail or could be
harmful. Despite some evidence of efficacy, dosage and timing of IVIG therapy, as well as the
question of its costs/benefit ratio still remain insufficiently documented and controlled trials
with definitive conclusions for clinical indications are needed.
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The basic immunomodulatory mechanisms of IVIG in autoimmune and inflammatory diseases
are twofold. One is its action on humoral immunity and the second involves mechanisms of
cell-mediated immunity. Both mechanisms interdependently involve modulation of
expression and function of Fc receptors, interference with complement activation and the
cytokine network, provision of antiidiotypic antibodies, modulation of dendritic cells, T and
B-cell activation and differentiation and their effector functions [75]. Analogous to normal
circulating immunoglobulins intravenous immunoglobulins have also anti-inflammatory
properties modulating systemic inflammation during various inflammatory states.
According to BSR guidelines [76] IVIG may be considered as an alternative therapy in patients
with refractory disease or in patients for whom conventional therapy is contraindicated, for
example, in the presence of infection, in severely ill patients or in pregnancy (grade of
recommendation B). In the management of refractory vasculitis it is important to identify
causes of the vasculitis, such as, intercurrent infection or malignancy. In many European
countries use of IVIG is limited for treatment of primary immune deficiencies where such
treatment has been known to be life saving. Even though use of intravenous immunoglobulins
in inflammatory diseases has been increased and a recent literature search revealed more than
150 off-label usages of IVIG, which included 6781 patients in clinical trials and 362 patients in
case reports [77].
Until present immunological mechanisms of immunomodulatory effect of IVIG are not clearly
known. In such context a question of adequate dosage appears in the relation of cost/benefits
of unlabeled treatment. It is supposed that patients who respond to high-dose IVIG therapy
would probably also respond to much lower doses, in many rheumatological indications
vasculitides not excluded. In addition to economic reasons, low-dose regimen would likely
help to reduce treatment related side effects. The lack of validated and generally accepted
outcome measures as well as prospective clinical studies makes it difficult to compare the effect
of different interventions in different cases [78].
7. Conclusions
Pulmonary-renal syndrome is a complex and heterogenous clinical picture involving rapid
progressive glomerulonephritis and pulmonary capillaritis based on inflammation and
necrosis of vessel wall. Morphological changes of pulmonary-renal syndrome are
consequences of immunologically mediated processes and the unconctrolled derangement of
the immune system could cause multiorgan dysfunction and fatal outcome.
The diagnostic procedure should focus on recognizing the earliest phases of the initiation and
progression of the inflammation through a reliable panel of immunological and organ specific
functional markers. In the near future novel diagnostic tools should be introduced in the
diagnosis and differential diagnosis of pulmonary-renal syndrome, including gene expression
profiles, cytokine profiles, markers of oxidative stress and many others.
Traditional clinical approach to treat pulmonary-renal syndrome was divided among
rheumatologists, nephrologist and pneumologists but the improving knowledge of its
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pathogenesis clearly indicates the need of an interdisciplinary team work incorporating
intensive care specialists and immunologists as well. This integrative approach could pave the
way toward the introduction of more efficient novel treatment regimes. Another challenge is
the high risk of relapses in these condition occurring up to 50 %, of the patients. Early
establishment of the exact diagnosis and effective etiology oriented treatment in such cases is
rather difficult task requiring further experimental and clinical research and cooperation of
different specialists.
Perspective therapeutic approaches based on contemporary immunological knowledge (B-cell
depletion, costimulatory molecule blockers, siRNAs controlling intracellular processes,
cytokine treatment) supported by clinical experience will bring benefits for induction and
maintenance of remission or also excluding the menacing catastrophic scenario of the disease.
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